|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2011-3-3
|
|
pubmed:abstractText |
Inhibition of the MDM2-p53 interaction has been shown to produce an antitumor effect, especially in MDM2 amplified tumors. The isoindolinone scaffold has proved to be versatile for the discovery of MDM2-p53 antagonists. Optimization of previously reported inhibitors, for example, NU8231 (7) and NU8165 (49), was guided by MDM2 NMR titrations, which indicated key areas of the binding interaction to be explored. Variation of the 2-N-benzyl and 3-alkoxy substituents resulted in the identification of 3-(4-chlorophenyl)-3-((1-(hydroxymethyl)cyclopropyl)methoxy)-2-(4-nitrobenzyl)isoindolin-1-one (74) as a potent MDM2-p53 inhibitor (IC(50) = 0.23 ± 0.01 ?M). Resolution of the enantiomers of 74 showed that potent MDM2-p53 activity primarily resided with the (+)-R-enantiomer (74a; IC(50) = 0.17 ± 0.02 ?M). The cellular activity of key compounds has been examined in cell lines with defined p53 and MDM2 status. Compound 74a activates p53, MDM2, and p21 transcription in MDM2 amplified cells and shows moderate selectivity for wild-type p53 cell lines in growth inhibition assays.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1520-4804
|
|
pubmed:author |
pubmed-author:AhmedShafiq USU,
pubmed-author:BennaceurKarimK,
pubmed-author:BlackburnTimothy JTJ,
pubmed-author:CleggWilliamW,
pubmed-author:DrummondCatherineC,
pubmed-author:EndicottJane AJA,
pubmed-author:GoldingBernard TBT,
pubmed-author:GriffinRoger JRJ,
pubmed-author:GruberJanJ,
pubmed-author:HaggertyKarenK,
pubmed-author:HardcastleIan RIR,
pubmed-author:HarringtonRoss WRW,
pubmed-author:HuttonClaireC,
pubmed-author:KempStuartS,
pubmed-author:LiuJunfengJ,
pubmed-author:LuXiaohongX,
pubmed-author:LunecJohnJ,
pubmed-author:McDonnellJames MJM,
pubmed-author:NewellDavid RDR,
pubmed-author:NobleMartin E MME,
pubmed-author:PayneSara LSL,
pubmed-author:RevillCharlotte HCH,
pubmed-author:RiedingerChristianeC,
pubmed-author:ValeurEricE,
pubmed-author:WatsonAnnaA,
pubmed-author:XuQingQ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
54
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1233-43
|
|
pubmed:meshHeading |
pubmed-meshheading:21314128-Antineoplastic Agents,
pubmed-meshheading:21314128-Cell Line, Tumor,
pubmed-meshheading:21314128-Cell Proliferation,
pubmed-meshheading:21314128-Crystallography, X-Ray,
pubmed-meshheading:21314128-Drug Screening Assays, Antitumor,
pubmed-meshheading:21314128-Humans,
pubmed-meshheading:21314128-Isoindoles,
pubmed-meshheading:21314128-Magnetic Resonance Spectroscopy,
pubmed-meshheading:21314128-Models, Molecular,
pubmed-meshheading:21314128-Molecular Structure,
pubmed-meshheading:21314128-Protein Binding,
pubmed-meshheading:21314128-Proto-Oncogene Proteins c-mdm2,
pubmed-meshheading:21314128-Stereoisomerism,
pubmed-meshheading:21314128-Structure-Activity Relationship,
pubmed-meshheading:21314128-Tumor Suppressor Protein p53
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
|
|
pubmed:affiliation |
Newcastle Cancer Centre, Northern Institute for Cancer Research and School of Chemistry, Bedson Building, Newcastle University, Newcastle NE1 7RU, United Kingdom. i.r.hardcastle@ncl.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
